1822-32-8

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
3-Piperidin-4-yl-propionic acid is used as a precursor in the synthesis of various pharmaceuticals for its ability to modulate biological pathways and processes. It plays a crucial role in the development of new drugs for the treatment of various diseases and conditions.
Used in Organic Synthesis:
3-Piperidin-4-yl-propionic acid is used as a building block in the synthesis of other organic compounds with potential pharmacological activity. Its versatile chemical structure makes it a valuable intermediate in organic synthesis, contributing to the creation of novel compounds with therapeutic potential.
Used in the Development of New Drugs:
3-Piperidin-4-yl-propionic acid is used as a key component in the development of new drugs, leveraging its ability to modulate biological pathways and processes. Its potential applications in treating various diseases and conditions make it a promising candidate for further research and development in the pharmaceutical industry.

InChI:InChI=1/C8H15NO2/c10-8(11)2-1-7-3-5-9-6-4-7/h7,9H,1-6H2,(H,10,11)

Upstream product

• 40500-10-5 3-(tetrahydro-2H-pyran-4-yl)propanoic acid 
• 84228-93-3 3-(pyridin-4-yl)acrylic acid 
• 98488-12-1 trans-3-(4'-pyridyl)acrylic acid hydrochloride 
• 154775-43-6 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid 
• 71879-55-5 ethyl 3-(piperid-4-yl)propionate 
• 301232-45-1 tert-butyl 4-(3-ethoxy-3-oxopropyl)-1-piperidinecarboxylate 
• 125552-89-8 4-(bromomethyl)tetrahydro-2H-pyran 
• 854830-57-2 tetrahydropyran-4-ylmethyl-malonic acid 
• 854830-56-1 diethyl 2-((tetrahydro-2H-pyran-4-yl)methyl)malonate 
• 123829-75-4 3-pyridin-4ylpropen-2-oic acid 
• 5337-79-1 3-(4-pyridinyl)-2-propenoic acid 
• 131417-49-7 3-[1-(acetyl)-4-piperidinyl]propionic acid 

Downstream Products

• 75999-93-8 3-(1-benzoyl 4-piperidyl)-propionic acid 
• 154775-43-6 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid 
• 169498-29-7 (R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid 
• 198958-88-2 [S-(R*,S*)]-β-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid 
• 305328-96-5 4-(3-benzylsulfanyl-2-carboxypropyl)piperidine-1-carboxylic acid tert-butyl ester 
• 124438-28-4 β-<1-(carbobenzoxy)-4-piperidine>propionyl chloride 
• 63845-33-0 1-[(phenylmethoxy)carbonyl]-4-piperidinepropanoic acid 
• 1613514-04-7 3,5-dichlorobenzyl 4-(3-(((1H-1,2,3-triazol-4-yl)methyl)amino)-3-oxopropyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS

The invention relates to a compound of the formula (I): in which k and j are independently 0 or 1, Y is a macrocycle in which the cycle includes 9 to 36 carbon atoms and is functionalised by three amino functions and by a chain for attaching the spacer arm Z via an X bond, Rc is a binding pattern with a receptor of the TNF superfamily, X is a chemical function for binding the Y group to the space arm, and Z is a bi-, tri- or tetra-functional spacer arm.

NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS

The invention concerns a compound of formula (I), wherein Y represents a macrocycle whereof the cycle comprises 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rc represents a group of formula H—Xa—Xb—Xc—Xd—Xe—(Xf)i—, wherein i represents 0 or 1, Xn is in particular selected among lysine, arginine, ornithine residues, Xb is in particular selected among glycine, asparagine, L-proline or D-proline residues, Xc et Xd are in particular selected among tyrosine, phenylalanine or 3-nitrotyrosine residues, Xe et Xf are in particular selected among the following amino acid residues: NH2—(CH2)n—COOH, n ranging from 1 to 10 or NH2—(CH2—CH2—O)m—CH2CH2COOH, m ranging from 3 to 6, provided that one at least of the amino acid residues Xa, Xb, Xc and Xd is different from the corresponding amino acid in the sequence of the natural CD40 143Lys-Gly-Tyr-Tyr146 fragment

NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR, wherein R is O-, -CH3 or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR or CR; or each of a, b, c and d is independently selected from CR or CR; each R and each R is independently selected from H, halo, -CR3, -OR, -COR, -SR, -S(O)tR (wherein t is 0, 1 or 2), -SCN, -N(R)2, -NRR, -NO2, -OC(O)R, -CO2R, -OCO2R, -CN, -NHC(O)R, -NHSO2R, -CONHR, -CONHCH2CH2OH, -NRCOOR, -SRC(O)OR, -SRN(R); n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO2-; or -CRR-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR, -SR, -CRR, -NRR, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.

Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFIa).

A Practical Synthesis of the Platelet Fibrinogen Antagonist, Elarofiban

Elarofiban is a novel, nonpeptide, orally active fibrinogen receptor antagonist useful for the treatment of platelet mediated thrombotic disorders (Costanzo, M. J.; Hoekstra, W. J.; Maryanoff, B. E. WO, 97/41102,1997). Herein we describe the process research that was carried out for the synthesis of elarofiban that eventually led to the development of a safe and cost-effective commercial scale process.

Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives

A process for preparing a compound of formula I wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen

Synthesis of substituted oxazolo[4,5-b]-pyridine derivatives

Synthesis of new functionnalized oxazolo[4,5-b]pyridines was described. 5-Bromo-3-hydroxy-2-aminopyridine was heated, in the presence of PPSE or PPA, with 4-cyanobenzoic acid, (4-piperidinyl)acetic or propanoic acid to afford 1,3-oxazolo derivatives. Intr

Dibasic inhibitors of human mast cell tryptase. Part 3: Identification of a series of potent and selective inhibitors containing the benzamidine functionality

A survey of charged groups and linkers for a series of symmetrical and unsymmetrical dibasic inhibitors is described, leading to several classes of potent and selective inhibitors. In particular, the benzamidine functionality was identified as the most potent charged group investigated.

Serine protease inhibitors

The invention relates to a cornound having formula (I), wherein A, B, X, Y and r are as defined in the description, or a prodrug thereof or a pharnnaceutically acceptable salt thereof. The compounds of the invention have anticoagulant activity and can be used in treating or preventing thrombin-related diseases.